Src inhibition blocks c-Myc translation and glucose metabolism to prevent the development of breast cancer

Cancer Research

Volumn 75, Issue 22, 2015, Pages 4863-4875

  Jain, Shalini ^a   Wang, Xiao ^a   Chang, Chia Chi ^a,b   Ibarra Drendall, Catherine ^c   Wang, Hai ^a   Zhang, Qingling ^a   Brady, Samuel W ^a,b   Li, Ping ^a   Zhao, Hong ^a   Dobbs, Jessica ^d   Kyrish, Matt ^d   Tkaczyk, Tomasz S ^d   Ambrose, Adrian ^c   Sistrunk, Christopher ^c   Arun, Banu K ^a   Richards Kortum, Rebecca ^d   Jia, Wei ^e   Seewaldt, Victoria L ^c   Yu, Dihua ^a,f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RICE UNIVERSITY   (United States)

^e UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; SARACATINIB; TAMOXIFEN; 1,3 BENZODIOXOLE DERIVATIVE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; GLUCOSE; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CELL GROWTH; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG TOLERABILITY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 BREAST CANCER; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GLUCOSE METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST TUMOR; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; ONCOGENE MYC; PHYSIOLOGY; PROTEIN SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIOXOLES; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GLUCOSE; HUMANS; MICE; PROTEIN BIOSYNTHESIS; QUINAZOLINES; RECEPTORS, ESTROGEN; SRC-FAMILY KINASES;

EID: 84955114584     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2345     Document Type: Article

References (54)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Cazzaniga M, Bonanni B. Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol 2012;2012:985620.
3. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62.
4. Yue W, Wang JP, Li Y, Bocchinfuso WP, Korach KS, Devanesan PD, et al. Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clin Cancer Res 2005;11:925s-30s.
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
6. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009;18:1157-66.
7. Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer 2013;14:26-38.
8. Castoria G, Giovannelli P, Lombardi M, De Rosa C, Giraldi T, de Falco A, et al. Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells. Oncogene 2012;31:4868-77.
9. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 2006;20:3120-32.
10. Zheng X, Resnick RJ, Shalloway D. Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi. Int J Cancer 2008;122:1999-2007.
11. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97:263-74.
12. Puls LN, Eadens M, Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist 2011;16:566-78.
13. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008;77:311-9.
14. Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, et al. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res 2012;18: 5911-23.
15. Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jorda M, et al. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Res Treat 2011;128:69-78.
16. den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol 2013;3:250.
17. Ibarra-Drendall C, Dietze EC, Seewaldt VL. Metabolic syndrome and breast cancer risk: is there a role for metformin? Curr Breast Cancer Rep 2011;3: 142-50.
18. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008;49 Suppl 2:24S-42S.
19. Dang CV. Links between metabolism and cancer. Genes Dev 2012;26: 877-90.
20. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009;15:6479-83.
21. Shajahan-Haq AN, Cook KL, Schwartz-Roberts JL, Eltayeb AE, Demas DM, Warri AM, et al. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol Cancer 2014;13:239.
22. Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, et al. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor statuswith standardized uptake value: microarray and immunohistochemical analysis. J Nucl Med 2010;51:543-50.
23. Hussein YR, Bandyopadhyay S, Semaan A, Ahmed Q, Albashiti B, Jazaerly T, et al. Glut-1 expression correlates with basal-like breast cancer. Transl Oncol 2011;4:321-7.
24. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009;461:109-13.
25. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011;17:461-9.
26. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, et al. TCPA: a resource for cancer functional proteomics data. Nat Methods 2013; 10:1046-7.
27. Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, et al. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 2009;16:195-207.
28. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10Amammaryepithelial acini grown in three-dimensional basement membrane cultures. Methods 2003;30:256-68.
29. Debnath J, Brugge JS. Modelling glandular epithelial cancers in threedimensional cultures. Nat Rev Cancer 2005;5:675-88.
30. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
31. Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 2010;16: 4876-83.
32. Liu KJ, He JH, Su XD, Sim HM, Xie JD, Chen XG, et al. Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. Int J Cancer 2013;132:224-35.
33. Vila PM, Park CW, Pierce MC, Goldstein GH, Levy L, Gurudutt VV, et al. Discrimination of benign and neoplastic mucosa with a high-resolution microendoscope (HRME) in head and neck cancer. Ann Surg Oncol 2012;19:3534-9.
34. Quinn MK, Bubi TC, Pierce MC, Kayembe MK, Ramogola-Masire D, Richards-Kortum R. High-resolution microendoscopy for the detection of cervical neoplasia in low-resource settings. PLoS One 2012;7: e44924.
35. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999;18:2149-64.
36. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202: 654-62.
37. Zhao FQ. Biology of glucose transport in the mammary gland. J Mammary Gland Biol Neoplasia 2014;19:3-17.
38. Young CD, Lewis AS, Rudolph MC, Ruehle MD, Jackman MR, Yun UJ, et al. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One 2011;6:e23205.
39. Pujol-Gimenez J, de Heredia FP, Idoate MA, Airley R, Lostao MP, Evans AR. Could GLUT12 be a potential therapeutic target in cancer treatment? A Preliminary Report. J Cancer 2015;6:139-43.
40. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000;275:21797-800.
41. Kristensen AR, Gsponer J, Foster LJ. Protein synthesis rate is the predominant regulator of protein expression during differentiation. Mol Syst Biol 2013;9:689.
42. Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A. Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. J Biol Chem 2002;277:42919-25.
43. Karni R, Gus Y, Dor Y, Meyuhas O, Levitzki A. Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation. Mol Cell Biol 2005;25:5031-9.
44. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189-99.
45. Topisirovic I, Sonenberg N. mRNA translation and energy metabolism in cancer: the role of the MAPK and mTORC1 pathways. Cold Spring Harb Symp Quant Biol 2011;76:355-67.
46. Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, et al. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest 2007;117:2205-15.
47. Marcotte R, Smith HW, Sanguin-Gendreau V, McDonough RV, Muller WJ. Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. Proc Natl Acad Sci U S A 2012;109: 2808-13.
48. Karim SA, Creedon H, Patel H, Carragher NO, Morton JP, Muller WJ, et al. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. J Pathol 2013;230:430-40.
49. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
50. Imayama I, Ulrich CM, Alfano CM, Wang C, Xiao L, Wener MH, et al. Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res 2012;72:2314-26.
51. Hursting SD, Dunlap SM, Ford NA, Hursting MJ, Lashinger LM. Calorie restriction and cancer prevention: amechanistic perspective. Cancer Metab 2013;1:10.
52. Houssami N, Hayes DF. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer? CA Cancer J Clin 2009; 59:290-302.
53. Independent UKPoBCS. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778-86.
54. Kyrish M, Dobbs J, Jain S, Wang X, Yu D, Richards-Kortum R, et al. Needle-based fluorescence endomicroscopy via structured illumination with a plastic, achromatic objective. J Biomed Opt 2013;18: 096003.